Alport syndrome
Conditions
Interventions
SGLT2i group:Henagliflozin: In the first cycle (from day 1 to day 60), patients assigned to the SGLT2i group were required to take the corresponding medication for one month (SGLT2i group: Henaglifloz
MRA group:Finerenone: The first cycle (from day 1 to day 60) involved patients randomly assigned to the MRA group who were required to take the corresponding medication for one month (MRA group: Finer
SGLT2i+MRA group:Henagliflozin+Finerenone: The first cycle (Day 1 to Day 60) involved the random allocation of patients to the combination therapy group, where they were required to take the correspon
Sponsors
peking university first hospital
Eligibility
Sex/Gender
All
Age
14 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age = 14 years old; 2. The patient or their first-degree relative has been diagnosed with Alport syndrome through renal biopsy; 3. Diagnosis of Alport syndrome through genetic testing, regardless of inheritance pattern; 4. Received stable doses of RAAS inhibitors within the 3 months prior to randomization; 5. eGFR > 40ml/min/1.73m2 (calculated by CKD-EPI formula); 6. Proteinuria has been detected in two consecutive tests (with at least a 2-week interval), and the 24-hour urine protein quantification (24hUTP) in two consecutive tests is >0.8g/d; 7. Willing to sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Merge other glomerular diseases; 2. Received immunosuppressive therapy (such as steroids, cyclosporine, hydroxychloroquine, tacrolimus, mycophenolate mofetil, and leflunomide) within the past 3 months, except for the following cases: a dose of =0.5 mg/kg prednisolone for non-renal indications (such as allergies or asthma) with continuous use of no more than 2 weeks; 3. History of diabetes; 4. Body mass index (BMI) 180mmHg); 8. Hypotension (SBP3 times the upper limit of normal); 10. History of malignant tumors, organ transplantation, or chronic liver disease; 11. Expected life span of less than 1 year; 12. Pregnant or lactating patients; 13. Female patients planning to become pregnant during the study period; 14. Patients receiving itraconazole, lopinavir-containing preparations, azanavir, darunavir, fosamprenavir-containing preparations, cobicistat-containing preparations, or clarithromycin; 15. Hyperkalemia (serum potassium >5.5mmol/L); 16. Patients with Addison's disease; 17. Participated in other drug clinical trials in the month prior to screening; 18. Patients who have lost the ability to act independently; 19. The investigator deems it inappropriate to participate in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24hUTP; | — |
Secondary
| Measure | Time frame |
|---|---|
| eGFR;UACR; | — |
Countries
China
Contacts
Public ContactXujie Zhou
Renal Department, Peking University First Hospital
Outcome results
None listed